|
NPPA releases draft version of proposed retail price calculation for five formulations
|
|
Our Bureau, New Delhi
October 23 , 2021
|
|
|
The National Pharmaceutical Pricing Authority (NPPA) has released draft version of proposed retail price calculation for five formulations, including a combination of telmisartan IP 40 mg and amlodipine besylate IP, which has a moving annual total (MAT) of Rs. 596.8 crore.
The telmisartan IP and amlodipine besylate IP combination, manufactured by Pure & Cure Healthcare Pvt Ltd and marketed by J B Chemicals & Pharmaceuticals Ltd, has been proposed with a retail price of Rs. 9.51 per tablet excluding goods and services tax (GST) while the claimed retail price was Rs. 20.32 per tablet. The proposed retail price is 34.5 per cent lower than the highest price in the market, which is Rs. 12.52 per tablet for Telsartan AM from Dr Reddy’s Laboratories Ltd.
Minimum price of Rs. 3.21 per tablet was reported by Systopic Laboratories Ltd, for its brand Newtel AM. 16 companies have one per cent or above market share for the formulation in the country.
Retail price of hard gelatin capsule containing rosuvastatin calcium IP equivalent to rosuvastatin 10 mg (as pills) along with Aspirin IP 75 mg (as enteric coated pills) manufactured by Synokem Pharmaceuticals Ltd and marketed by Cadila Pharmaceuticals was fixed at Rs. 5.99 per capsule excluding GST while the claimed retail price was Rs 12.50 per capsule. The MAT of the formulation is around Rs. 73.81 crore, and there are 13 players with one per cent or above market share.
Retail price of capsule containing rosuvastatin calcium IP equivalent to rosuvastatin 20 mg (as pellets) along with clopidogrel bisulphate IP equivalent to clopidogrel 75 mg (as pellets), manufactured by Synokem Pharma and marketed by Cadila Pharma, has been proposed at Rs. 19.64 per capsule, which was also the claimed retail price. The MAT of the formulation is Rs. 23.51 crore and there are five companies which has one per cent or above market share.
Formulation of azelnidipine IP 8 mg and telmisartan IP 40 mg manufactured by Akums Drugs & Pharmaceuticals Ltd and marketed by IPCA Laboratories has been proposed with a retail price of Rs. 11.37 per tablet excluding GST, while the claimed retail price was Rs. 12.50 per tablet.
Gel containing lignocaine hydrochloride IP 2.0% w/w + chlorhexidine gluconate IP 1.0% w/w + metronidazole IP 1.0% w/w manufactured by Curetech Skincare and marketed by J B Chemicals and Pharmaceuticals has been proposed at a retail price of Rs. 3.48 per gram, as against claimed retail price of Rs. 4.57 per gram.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|